Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (48)

« Back to Publications

Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.

Turkalj S. et al, (2026), Blood, 147, 613 - 632

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Clonal tracing with somatic epimutations reveals dynamics of blood ageing.

Scherer M. et al, (2025), Nature, 643, 478 - 487

Detecting and quantifying clonal selection in somatic stem cells.

Körber V. et al, (2025), Nat Genet, 57, 1718 - 1729

Protocol for high-quality RNA sequencing, cell surface protein analysis, and genotyping in single cells using TARGET-seq.

Jakobsen NA. et al, (2025), STAR Protoc, 6

Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1.

Agarwal P. et al, (2025), Nature, 642, 201 - 211

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

Turkalj S. et al, (2024)

Risk Stratification in Older Intensively Treated Patients With AML.

Versluis J. et al, (2024), J Clin Oncol, 42, 4084 - 4094

Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Tables and Figures from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Tables and Figures from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Load More